EYPT - ピ―シビダ （EyePoint Pharmaceuticals Inc.） ピ―シビダEYPTのチャート
EYPTの企業情報
| symbol | EYPT |
|---|---|
| 会社名 | EyePoint Pharmaceuticals Inc （ピ―シビダ） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Biotechnology: Laboratory Analytical Instruments |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アイポイント・ファーマシューティカルズ(Eyepoint Pharmaceuticals Inc.)(旧名：pSivida Corp.)は主に慢性眼疾患の治療用の薬物送達製品を開発する。同社は目の裏目の病気の治療のための3つの製品を開発した。後部セグメントブドウ膜炎のためのMedidurは、主要な第III相臨床試験にあるリード製品候補である。糖尿病性黄斑浮腫（DME）のILUVIENは、米国および欧州連合（EU）諸国で販売されている主要ライセンス製品である。また、Retisertを含む。Medidurは、眼の後部に影響を与える慢性非感染性ブドウ膜炎（後部ブドウ膜炎）を治療するように設計される。ILUVIENは、単回注射からDMEの治療を提供する注射可能なマイクロインサートである。Retisertは、後区域ブドウ膜炎の治療を提供するインプラントである。同社の製品開発プログラムは、DurasertとTethadurの2つの技術プラットフォームを利用して、慢性疾患治療薬と生物製剤を提供することに重点を置く。 ピ―シビダは、米国の医薬品会社。目の奥の慢性疾患の治療に焦点を当てた医薬品「Durasert」と「Tethadur」を開発。また、製品候補「Medidur」は、第3相臨床試験段階である。同社の主要製品「ILUVIEN」は、欧州連合(EU)で承認され、米国食品医薬品局(FDA)では承認が保留されている。 EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasert® sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion. |
| 本社所在地 | 480 Pleasant Street Watertown MA 02472 USA |
| 代表者氏名 | Goran A. Ando ゴラン・アンドド |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-926-5000 |
| 設立年月日 | 31868 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 44人 |
| url | www.eyepointpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eypt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -25.12600 |
| 終値（lastsale） | 3.28 |
| 時価総額（marketcap） | 244399517.44 |
| 時価総額 | 時価総額（百万ドル） 250.36050 |
| 売上高 | 売上高（百万ドル） 2.96100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 228.89350 |
| 当期純利益 | 当期純利益（百万ドル） -53.17100 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Eyepoint Pharmaceuticals Inc revenues decreased 61% to $3M. Net loss increased from $18.5M to $53.2M. Revenues reflect United States segment decrease of 62% to $2.9M. Higher net loss reflects Research and Development Expense increase of 12% to $14.9M (expense) General and administrative increase of 3% to $10.1M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.52 to -$1.15. |
EYPTのテクニカル分析
EYPTのニュース
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2022 Results - Earnings Call Transcript 2022/08/03 19:05:18 Seeking Alpha
EyePoint Pharmaceuticals, Inc. (NASDAQ:NASDAQ:EYPT) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker -…
EyePoint Pharmaceuticals Reports In-Line Q2 EPS By Investing.com 2022/08/03 11:30:03 Investing.com
EyePoint Pharmaceuticals Reports In-Line Q2 EPS
EyePoint Pharmaceuticals GAAP EPS of -$0.52 misses by $0.01, revenue of $11.6M beats by $0.74M (NASDAQ:EYPT) 2022/08/03 11:01:41 Seeking Alpha
EyePoint Pharmaceuticals press release (EYPT): Q2 GAAP EPS of -$0.52 misses by $0.01.Revenue of $11.6M (+28.7% Y/Y) beats by $0.74M."We expect the cash, cash equivalents and…
Earnings Preview For EyePoint Pharmaceuticals 2022/08/02 18:41:42 Benzinga
EyePoint Pharmaceuticals (NASDAQ: EYPT ) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here''s what investors need to know before the announcement. Analysts estimate that EyePoint Pharmaceuticals will report an earnings per share (EPS) of $-0.52. EyePoint Pharmaceuticals bulls will hope to hear the company to announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences 2022/08/02 11:00:00 GlobeNewswire
WATERTOWN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ will present at the following upcoming conferences:
EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing 2022/03/09 17:18:02 Benzinga
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT ) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing credit facility with CRG Servicing LLC . Under the terms of the new agreement, a $30 million term loan facility and an asset-based revolving credit … Full story available on Benzinga.com
EyePoint Pharmaceuticals signs loan agreement for $45M with Silicon Valley Bank 2022/03/09 12:47:51 Seeking Alpha
EyePoint Pharmaceuticals (EYPT) entered into a loan agreement providing for senior secured credit facilities in the amount of $45M with Silicon Valley Bank to replace its existing…
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q4 2021 Results - Earnings Call Transcript 2022/03/03 20:10:06 Seeking Alpha
DBV Technologies, EyePoint top healthcare gainers; NuCana, MediWound lead losers'' pack 2022/03/03 15:00:42 Seeking Alpha
DBV Technologies DBVT +16%. EyePoint Pharmaceuticals (EYPT) +14%. NuCana (NCNA) -54%. MediWound (MDWD) -15%.
EyePoint Pharmaceuticals GAAP EPS of -$0.59 misses by $0.03, revenue of $11.54M beats by $1.75M 2022/03/03 12:02:40 Seeking Alpha
EyePoint Pharmaceuticals press release (EYPT): Q4 GAAP EPS of -$0.59 misses by $0.03.Revenue of $11.54M (+61.9% Y/Y) beats by $1.75M.
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q3 2021 Results - Earnings Call Transcript 2021/11/03 16:27:05 Seeking Alpha
EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments 2021/11/03 11:00:00 Intrado Digital Media
– Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists (ASRS) –
EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer 2021/11/01 11:00:00 Intrado Digital Media
WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Jay S. Duker, M.D. as Chief Operating Officer (COO). Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoints Board of Directors since 2016. In his new full-time role as COO, Dr. Duker will be responsible for overseeing all clinical development, research, product development and manufacturing.
Head-To-Head Analysis: EyePoint Pharmaceuticals (NASDAQ:EYPT) & Cytek BioSciences (NASDAQ:CTKB) 2021/10/30 13:20:49 Dakota Financial News
EyePoint Pharmaceuticals (NASDAQ:EYPT) and Cytek BioSciences (NASDAQ:CTKB) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability. Profitability This table compares EyePoint Pharmaceuticals and Cytek BioSciences net margins, return on equity and return []